"Korean dental lab skills, the U.S. didn't know" — Global deal nets K-dental 12 billion won

[For more diverse corporate information on the startups mentioned in this article, visit Unicorn Factory's big data platform 'Data Lab'.]

38%. This is the percentage of dental prosthetics manufactured overseas in the U.S., as revealed by the National Association of Dental Laboratories (NADL). Over 40 countries, including China, Vietnam, and Mexico, have labs fulfilling orders from U.S. dentists, with an outsourcing scale reaching $1.32 billion (approximately 2 trillion won) annually. The issue lies in quality. The rework rate for prosthetics from these countries stands at 8–12%. This means that out of every 10 ordered prosthetics, at least one is defective and must be remade.

In contrast, the average rework rate for Korean labs is just 1–3%, only a quarter of major outsourcing nations. Production costs are also less than half of U.S. local prices. Startup Inobid capitalized on this structural gap to build its business model and launched the global dental lab service 'Dentlink'.

Recently, Inobid secured 12 billion won in Series B funding led by SBVA (formerly SoftBank Ventures Korea). IBK Industrial Bank of Korea joined as a new investor in this round, while Wonik Investment Partners, TransLink Investment, and Murex Partners also participated in follow-on investments. Inobid's cumulative investment total now stands at 19 billion won.

The rationale behind SBVA's decision to invest in Inobid lies in the strengths of Korea's dental lab infrastructure. South Korea is one of the few countries that enforces a strict national licensing system, requiring graduation from a university dental laboratory program to obtain a license. Thanks to systematic curricula and mandatory on-site training, skilled personnel are consistently produced. Additionally, major domestic implant companies have further enhanced lab technicians' capabilities through their own training centers.

Jung Na-young, Senior Reviewer at SBVA, stated, "Dental laboratory work is a unique industry in Korea that allows for simultaneous competitiveness in both quality and price." She added, "We confirmed that the product-market fit (PMF) of the business model connecting this structural advantage to the global market has been validated, which led us to decide on the investment."

The Senior Reviewer highlighted Inobid's '95% paid customer retention rate' and '0.6% rework rate.' The proportion of new customers acquired through dentist referrals also exceeds 40%. A virtuous cycle has been established where overseas dentists who experience the product do not churn but voluntarily recommend it to their colleagues, leading to customer growth.

The secret to reducing the rework rate to just 0.6%—well below both foreign competitors (8–12%) and the domestic average (1–3%)—lies in the digital standardization of the entire lab process.

When a dentist transmits data via an intraoral scanner, Dentlink's AI determines production feasibility in real time. The system then quantifies and conveys the specific dentist's past preferences and order requirements to partner lab technicians. Previously dependent on technician skill or visual inspection for tasks like shade matching guides, all such processes are now standardized through app-based data. The Senior Reviewer evaluated, "The steady accumulation of dentists' preferences and feedback as data has led to today's superior quality competitiveness."

Inobid generates 100% of its revenue from overseas. It currently provides services in six countries centered on the U.S. and Australia, including Canada, New Zealand, Singapore, and the UK. The company's target revenue for this year is 18 billion won. Notably, in the U.S., it has secured dental clients across all 28 states, not limited to specific regions.

In fact, Straumann, the world's leading implant manufacturer, recognized Dentlink's data competitiveness first and even proposed a collaboration. In the Australian market, after partnering with Straumann, the number of transacting clinics surged more than threefold.

SBVA is also focusing on maximizing penetration rates in already-validated core markets rather than aggressively expanding into new countries. The Senior Reviewer noted, "Considering the total size of the dental markets in the U.S. and Australia, Inobid's current penetration rate is merely at the starting stage, leaving unlimited growth potential." She emphasized, "Just as seen with the Straumann case, collaboration requests are pouring in from global intraoral scanner and implant companies, so expanding partnerships with them will be a key growth driver moving forward."

The next market Inobid is eyeing is the aesthetic prosthetics sector. It is preparing to launch laminate products in the third quarter of this year. The Senior Reviewer pointed out, "Korea has highly active laminate procedures with world-class production quality, but overseas markets like the U.S. and Australia remain a blue ocean that has not yet fully blossomed."

In particular, unlike general crown prosthetics for therapeutic purposes, laminates are a market where patients tend to search for and choose treatment methods themselves. The high unit price ensures good profitability, and due to the nature of the procedure prioritizing finish and aesthetics over speed, it enjoys relative freedom from delivery lead time pressure.

The Senior Reviewer assessed, "This is an area where we can build a brand that patients recognize and trust first, rather than just labs chosen by dentists." She added, "It will serve as a foothold to expand beyond the B2B (business-to-business) focused business structure into B2C (business-to-consumer) branding."

Inobid plans to focus this investment on expanding into U.S. and Australian markets, establishing a domestic robot-linked automated prosthetics manufacturing center, and securing R&D talent for AI-based dental prosthetic services. The manufacturing center centralizes precision equipment that small partner labs cannot afford individually, enabling shared use.

Koo Jin-hyuk, the Noh Ba-i-deu (CEO), stated, "This funding round is an important milestone demonstrating that Inobid is addressing the industry's fundamental problem of dental prosthetic rework on a global scale." He continued, "Using this funding as a springboard, we will further advance our technology and manufacturing infrastructure to innovate the global dental lab market."

[MoneyToday startup media platform Unicorn Factory]